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Abstract 
Background: Human immunodeficiency virus type 1 (HIV-1) must take advantage of its own proteins with two or 
more functions to successfully replicate. Although many attempts have been made to determine the function of viral 
proteins encoded in the HIV-1 genome, the role of the p2 peptide, a spacer between the capsid and the nucleocapsid 
in HIV-1 Gag in early-phase HIV infection still remains unclarified.
Results: In this study, we show that the p2 peptide enhances HIV-1 acute infection by increasing intracellular ATP 
production via the activation of mitochondrial cytochrome c oxidase (MT-CO) involved in the respiratory chain. We 
found that cell-permeable p2-peptide-treated cells were more effectively infected by HIV-1 than control cells. To 
characterize the effect of the p2 peptide on HIV-1 replication in MAGIC-5 cells, various HIV-1 cDNA products were 
measured by quantitative real-time PCR. The levels of the late (R/gag), 2-LTR circular (2-LTR), and integrated (Alu) forms 
of viral cDNAs increased in the presence of the p2 peptide. Interestingly, yeast two-hybrid analysis revealed a novel 
interaction between the p2 peptide and the mitochondrial intermembrane space domain (N214–F235) of MT-CO subu-
nit I (MT-CO1). Mutational analysis indicated that Gln6 in the p2 peptide is important for the interaction with MT-CO1. 
The p2 peptide activated MT-CO1 in vitro in a concentration-dependent manner, and fluorescence-microscopy analy-
sis demonstrated that the p2 peptide had a significant effect on mitochondrial targeting. Furthermore, the analysis 
of HIV-1 lacking a functional p2 peptide demonstrated the inhibition of intracellular ATP production in MT-4 cells and 
monocyte-derived macrophages (MDMs) and a decrease in reverse transcription efficiency following infection of 
MT-4 cells and MDMs.
Conclusions: These findings provide evidence that the p2 peptide is a viral positive allosteric modulator of MT-CO 
and the increased intracellular ATP production after HIV infection in a p2-peptide-dependent manner is essential for 
efficient reverse transcription in early-phase HIV-1 infection.
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Background
All of the lentiviral Gag proteins contain a spacer pep-
tide between the CA and NC domains [1–5]. In the case 
of HIV, the spacer peptide p2 is synthesized as part of 
the Gag and Gag-Pol precursors. Some studies demon-
strated that the p2 peptide functions in the late phase of 
the HIV-1 life cycle. Kaye and Lever reported that the p2 
domain of the HIV-1 Gag precursor could contribute to 
the specific HIV-1 RNA encapsidation [6]. Pettit et  al. 
reported that the p2 domain of the HIV-1 Gag precursor 
regulates sequential proteolytic processing and ensures 
the correct assembly of the virion [7]. Our previous study 
suggests that the p2 peptide is an inherent suicidal inhibi-
tor of HIV-1 protease, because the p2 peptide inhibits the 
proteolytic cleavage of the recombinant Gag precursor 
protein into functional structural units [matrix (MA) and 
CA proteins] in vitro [8]. However, the virological func-
tion of the p2 peptide still remains unknown in the early 
phase of the viral life cycle.
The p2 peptide actually exists in viral particles. Pettit 
et al. reported that the p2 domain is finally cleaved from 
the C-terminus of the CA protein to produce fully infec-
tious virions [7]. In our previous study, the p2 peptide 
was detected in HIV-1 particles by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry 
[8]. During HIV-1 virion release, each immature virion 
contains approximately 2400 Gag precursors [9] and 
approximately 120 Gag-Pol precursors [10], suggesting 
that a budded mature particle consequently has ∼2400 
p2 peptides, which in a 120-nm-diameter sphere corre-
sponds to a p2 peptide concentration of approximately 
4 mM. Therefore, the p2 peptide at a high concentration 
may be focally released into the cytoplasm of target cells 
after the viral entry.
In this study, we show the virological function of the p2 
peptide in the early phase of the viral life cycle. We dem-
onstrated that the p2 peptide released into the cytoplasm 
during HIV uncoating following the viral entry is targeted 
towards the mitochondrial intermembrane space domain 
(N214–F245) of MT-CO1 involved in the respiratory chain 
and increases MT-CO activity. Consequently, intracel-
lular ATP content increased in a p2-peptide-dependent 
manner, which leads to an efficient acute HIV infection. 
These findings are the first to show that the activity of 
MT-CO1 is positively regulated by the exogenous viral 
spacer p2 peptide. These findings reveal a novel regula-
tory step of early HIV-1 infection.
Results
HIV‑1 p2 peptide enhanced HIV‑1 infection and indirectly 
enhanced HIV‑1 reverse transcription
During HIV uncoating following the viral entry, the 
p2 peptide is released from HIV particles into the 
cytoplasm. To effectively deliver the p2 peptide into cells 
across the lipid bilayer, a synthetic HIV-1 Tat-p2 pep-
tide (GRKKRRQRRRARVLAEAMSQVTNTATIM) that 
included residues 359–376 of the HIV-1 Gag precursor 
fused with the arginine-rich domain (G48–R57) of HIV-1 
Tat was generated [11]. To investigate the effect of the 
p2 peptide on HIV infection, MAGIC-5 cells [1  ×  104 
CCR5- and CXCR4-expressing HeLa/CD4(+) cells] were 
infected with HIV-1JRFL in the presence or absence of the 
Tat-p2 peptide or Tat-scrambled peptide (GRKKRRQR-
RRARVLIAVSNMQTTAMATE). The results indicated 
that the increase in HIV-1JRFL infectivity is dependent 
on the concentration of the Tat-p2 peptide (Fig.  1a). In 
contrast, the Tat-scrambled peptide did not increase the 
HIV-1JRFL infectivity (Fig. 1a).
To clarify the relationship between the increased infec-
tivity and the treatment with the p2 peptide, we carried 
out quantitative real-time PCR analysis to quantify the 
late DNA in reverse transcription, 2-LTR circles and inte-
grated proviruses by nested Alu-PCR in Tat-p2-peptide-
treated MAGIC-5 cells. The treatment with the Tat-p2 
peptide showed significant increases in the levels of the 
late form (R/gag), 2-LTR circle form and Alu-PCR prod-
ucts (Fig.  1b). These findings suggest that the increased 
HIV-1 infectivity is linked to a higher efficiency of the late 
reverse transcription process. Furthermore, we deter-
mined whether the levels of the late forms (R/gag) of viral 
cDNA products are increased by the intracellular expres-
sion of the p2 peptide. The p2 peptide was expressed in 
MAGIC-5 cells as a fusion protein with the p2 peptide 
fused to the C terminus of EGFP (i.e., the EGFP-p2x1 
peptide). As expected, the intracellular expression of the 
EGFP-p2x1 peptide resulted in a significant increase in 
the levels of the late forms (R/gag) of viral cDNA prod-
ucts (Fig. 1c), suggesting that the p2 peptide functions as 
an allosteric effector of HIV reverse transcriptase (RT). 
However, in  vitro RT assay showed that the p2 peptide 
had no significant direct effect on the enzymatic activity 
of RT (Fig. 1d). These findings suggest that the p2 peptide 
is related to some contributory cellular environmental 
factors that promote reverse transcription.
HIV‑1 p2 peptide interacted with the mitochondrial 
intermembrane space domain (N214–F235) of MT‑CO1
To gain a better understanding of the function of the p2 
peptide, we carried out yeast two-hybrid (Y2H) screening 
to identify cellular factors that potentially interact with 
the p2 peptide. In the screening, the cDNA sequences 
of positive clones revealed that the p2 peptide interacted 
with the mitochondrial intermembrane space domain 
(N214–F235) of MT-CO1. To validate the interactions 
between the p2 peptide and MT-CO1, the bait plasmid 
(pGBKT7-p2) and the prey plasmid derived from the 
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mitochondrial intermembrane space domain (N214–F235) 
of MT-CO1 (pGADT7-MT-CO1) were cotransformed 
into the yeast strain (Y2HGold), and the yeast was grown 
on DDO/X (double dropout medium lacking tryptophan 
and leucine, and supplemented with X-α-Gal) and QDO/
X/A (quadruple dropout medium lacking adenine, his-
tidine, tryptophan and leucine, and supplemented with 
X-α-Gal and aureobasidin A) plates. As shown in Fig. 2a, 
the growth of blue colonies on both DDO/X and QDO/
X/A plates indicated the positive interaction between the 
p2 peptide and MT-CO1. Furthermore, alanine scanning 
mutagenesis (E2A, M4A, S5A, Q6A) in the highly con-
served AEAMSQ motif of the p2 peptide among HIV-1 
group M was carried out to determine the contribution 
of a specific residue to the interaction between the p2 
peptide and MT-CO1. Figure  2b shows that pGBKT7-
p2(Q6A) and pGADT7-MT-CO1 cotransformants 
appeared white on the DDO/X plate and did not grow 
on the QDO/X/A plate, suggesting that the highly con-
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Fig. 1 HIV-1 p2 peptide enhanced HIV-1 infection and enhanced HIV-1 reverse transcription. a The effect of the p2 peptide on HIVJRFL infection was 
investigated by MAGIC-5 assay. No significant cytotoxicity of the Tat-p2 peptide- or Tat-scrambled peptide-containing medium was observed. The 
significance of difference (Student’s t test) is indicated as follows: **p < 0.01 vs control. The mean values of at least three independent experiments 
are shown. b, c Effect of p2 peptide on reverse transcription in MAGIC-5 cells. Tat-p2-peptide-treated (b) or EGFP-p2x1-peptide-transduced (c) 
MAGIC-5 cells were infected with HIVJRFL (b, 100 ng of HIV p24) or VSV-G-pseudotyped HIVNL-CHΔenv WT (c, 10 ng of HIV p24). The levels of late viral 
cDNA products (Late), 2-LTR products (2-LTR) or Alu-PCR products (Alu) were determined by quantitative real-time PCR analysis. The significance of 
difference (Student’s t test) is indicated as follows: **p < 0.01. The mean values of at least three independent experiments are shown. The error bars 
denote the standard deviation. d Effect of p2 peptide on enzymatic activity of HIV-1 RT. In vitro RT activity assay was performed at a ratio of 1:40 of 
RT to each peptide (Tat-p2 peptide, Tat-peptide, or p2 peptide). The value in the control experiment (RT only) was set as 100 %. The mean values of 
at least three independent experiments are shown
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for the interaction between the p2 peptide and the mito-
chondrial intermembrane space domain (N214–F235) of 
MT-CO1.
HIV‑1 p2 peptide increased MT‑CO activity
To investigate the effect of the p2 peptide on MT-CO1, 
the expression level of MT-CO1 was analyzed by western 
immunoblot analysis using an anti-Xpress antibody and 
MAGIC-5 cells expressing the EGFP-p2x1 peptide. At 
48 h post-transfection, no significant change in MT-CO1 
expression level was observed (Fig. 3a). Next, to examine 
the allosteric effect of the p2 peptide on the enzymatic 
activity of MT-CO1, in vitro cytochrome c oxidase activ-
ity assay was performed in accordance with the manu-
facturer’s instruction manual. The exposures of MT-CO 
positive control or MT-CO1 in mitochondrial fractions 
from MAGIC-5 cells to 80 or 160  µM p2 peptide were 
associated with the positive allosteric effect on MT-CO 
activity in a concentration-dependent manner (Fig.  3b). 
In contrast, the p2-peptide-dependent allosteric effect 
was significantly inhibited by 10 mM sodium azide as a 
reversible inhibitor of MT-CO (Fig. 3c).
HIV‑1 p2 peptide was targeted to the mitochondrial 
intermembrane space
To study the mitochondrial localization of the p2 peptide, 
we examined HeLa cells that were transfected with the 
pEGFP-p2x1 peptide, pEGFP-p2x9 peptide, or pEGFP-
p2x17 peptide, which contained nine or seventeen tan-
dem repeats of the p2 peptide. The expression of the 
EGFP-p2 peptides was confirmed by confocal micros-
copy (Fig.  3d). We observed a strong EGFP-p2 peptide-
specific signal that partly overlapped with the signal of 
the mitochondrion-selective marker MitoTracker in a 
p2-peptide-length-dependent manner (Fig. 3d). To deter-
mine whether the EGFP-p2x1 peptide is located inside or 
outside the mitochondria, we next assessed the sensitiv-
ity of the mitochondria-associated EGFP-p2x1 peptide 
to proteinase K. For this experiment, a freshly prepared 
mitochondrial fraction was incubated with proteinase 
K, and the mitochondrial proteins were immunoblot-
ted for the EGFP-p2x1 peptide, Bcl-2, and MT-CO1. 
As shown in Fig.  3e, MT-CO1, which is embedded in 
the inner mitochondrial membrane, was fully protected 

























Fig. 2 HIV-1 p2 peptide interactd with mitochondrial cytochrome c oxidase. a For cotransformation assay using the positive clones from the initial 
Y2H screening, the bait plasmid (pGBKT7-p2) and prey plasmid encoding the mitochondrial intermembrane space domain (N214–F235) of MT-CO1 
(pGADT7-MT-CO1) were cotransformed into Y2Hgold to confirm the interactions in yeast and grown on DDO/X and QDO/X/A. Growth on QDO/X/A 
indicated interaction between the p2 peptide and MT-CO1. b P2 mutants (E2A, M4A, S5A, and Q6A) were used to investigate their interactions with 
MT-CO1. The mitochondrial intermembrane space domain (N214–F235) of MT-CO1 interacted with the mutant E2A, M4A, and S5A p2 peptides, but 
not with the Q6A mutant p2 peptide




































































































Fig. 3 Mitochondrial cytochrome c oxidase was activated by the p2 peptide. a MAGIC-5 cells transfected with pcDNA4/EGFP-p2x1 were subjected to 
western immunoblot analysis for MT-CO1 or actin expression. The expression of the EGFP-p2x1 peptide in MAGIC-5 cells did not affect the expres-
sion of both MT-CO1 and actin. A representative result is shown from at least three independent experiments. b MT-CO activity measurements show 
that the p2 peptide activates the enzymatic activity of MT-CO-positive control or native MT-CO1 in mitochondrial fractions from MAGIC-5 cells. Unit 
Definition: One unit oxidizes one micromole of ferrocytochrome c per minute at 25 °C, pH 7.0. **p < 0.01 versus control; Repeated measures ANOVA 
and Dunnett’s post hoc test (n = 10). c Sodium azide completely inhibited p2-peptide-dependent enzymatic activation of MT-CO. The significance of 
difference (Student’s t test) is indicated as follows: **p < 0.01 (n = 5). d Confocal laser scanning microscopy was used for observation of fluorescence 
in HeLa cells expressing EGFP, or the EGFP-p2x1, EGFP-p2x9, or EGFP-p2x17 peptide. EGFP fluorescence is shown in the left micrographs, MitoTracker-
derived fluorescence is shown in the second column of the micrographs, and an overlay of EGFP and MitoTracker signals (Merge) is shown in the right-
most column of micrographs. The nuclei were made visible with DAPI staining (Third column). EGFP-p2 peptide fusion proteins (EGFP-p2x1 peptide, 
EGFP-p2x9 peptide, or EGFP-p2x17 peptide) colocalized with the mitochondrial marker MitoTracker. A representative image from three independent 
experiments is shown. e Mitochondria obtained from MAGIC-5 cells expressing the EGFP-p2x1 peptide were incubated with proteinase K (0.05 μg/
ml). The lysate of the mitochondrial protein was subjected to SDS-PAGE and examined by western immunoblot analysis using an anti-Xpress, anto-
Bcl2 or anti-MT-CO1 antibody. A representative result is shown from at least three independent experiments
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with the external mitochondrial membrane, was com-
pletely degraded. Interestingly, a significant fraction of 
the EGFP-p2x1 peptide was not degraded by proteinase 
K, suggesting that a portion of the EGFP-p2x1 peptide 
is located inside the mitochondria and is targeted to the 
mitochondrial intermembrane space.
p2‑peptide increased intracellular ATP content in MT‑4 
cells
Because the p2 peptide was associated with the posi-
tive allosteric effect on MT-CO activity, we next 
examined whether HIV-1 infection increases the intra-
cellular ATP content in HIV-1 target cells in a p2-pep-
tide-dependent manner. The CXCR4-tropic p2(Q6A) 
mutant virus (HIVNL-CH p2(Q6A)) showed normal CA 
processing (Fig.  4a upper figure). To further demon-
strate the effect of p2(Q6A) mutation on viral entry, we 
isolated the cytosolic fraction of target cells postinfec-
tion, as described previously by Maréchal et  al. [12], 
who reported that the measurement of cytosolic p24 
after virus infection is a reliable assay for the assess-
ment of viral entry events leading to actual cell infec-
tion. The viral entry assay indicated that the entry level 
of p2(Q6A) mutant virus was comparable to that of 
the WT virus in the cytosolic fraction (Fig.  4a lower 
figure). However, the p2(Q6A) mutant virus could not 
efficiently increase the intracellular ATP content in the 
HIV-1-permissive T cell line MT-4 cells as compared 
with that in the WT virus at 12 h postinfection (Fig. 4b). 
Furthermore, the p2(Q6A) mutant virus showed a sig-
nificant decrease in the level of the late viral cDNA 
product (Fig. 4c).
p2‑peptide increased intracellular ATP content in MDMs
Next, we studied whether this was also the case in the 
other major target of HIV-1, primary macrophages. 
Monocytes were cultured in differentiation medium and 
the resulting MDMs were characterized on the fifth day 
of differentiation in terms of the functional marker CD14, 
CD4, and CCR5 by flow cytometric analysis. As shown in 
Fig. 5a, the prepared cells showed a typical morphology 
of MDMs, and CD4 and CCR5 were virtually detected 
on CD14-positive MDMs. ATP bioluminescence assay 
demonstrated that the intracellular ATP content in 
MDMs was about four fold lower than that of MT-4 cells 
in the absence of HIV infection (Fig.  5b). Furthermore, 
as expected, the CCR5-tropic p2(Q6A) mutant virus 
(HIVAD8 p2(Q6A)) could not efficiently increase the intra-
cellular ATP content in MDMs as compared with that in 
the WT virus at 12 h postinfection (Fig. 5c). Finally, the 
single-round replication-defective VSV-G-pseudotyped 
HIVNL-CHΔenv p2(Q6A) (10  ng of HIV p24) also showed a 
significant decrease in the level of the late viral cDNA 
product (Fig.  5d). These findings show that the p2 pep-
tide plays a key role in the increase in intracellular ATP 






























































































Fig. 4 p2-peptide increased intracellular ATP content in MT-4 cells. (a, upper figure) The p2(Q6A) mutation did not affect normal CA processing. 
(a, lower figure) The entry efficiency of the p2(Q6A) mutant virus was determined in terms of the amount of CA protein released into the cytosolic 
fraction of MT-4 cells (see “Methods”). b The infection with the HIVNL-CH WT virus increased the intracellular ATP content in MT-4 cells. In contrast, the 
intracellular ATP content after HIVNL-CH p2(Q6A) infection was not efficiently increased. **p < 0.01, Nonrepeated measures ANOVA and Dunnett’s test. 
The mean values of at least three independent experiments are shown. c p2(Q6A) mutant virus showed a significant decrease in the level of the 
late viral cDNA product in MT-4 cells as compared with that in the WT virus. Reverse transcription products were determined by quantitative PCR 
analysis using late-stage primers (R/gag), as described in “Methods”. To normalize the amount of cellular DNA (100 ng) in the samples, a primer pair 
complementary to the first exon of the human β-actin gene was used
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Discussion
Although many attempts have been made to determine 
the function of viral proteins encoded in the HIV-1 
genome, the role of the p2 peptide in early-phase HIV 
infection has remained unclarified because it has been 
very difficult to study the peptide owing to a lack of an 
efficient assay for this viral low-molecular-weight p2 pep-
tide. In this study, the cell-permeable p2-peptide-treated 
cells were more effectively infected with HIV-1 than con-
trol cells (Fig.  1). The p2-peptide-dependent increase in 
HIV-1 infectivity is associated with a higher efficiency of 
the late reverse transcription process (Fig. 1b). However, 
in  vitro RT assay showed that the p2 peptide showed 
no significant direct effect on the enzymatic activity 
of RT (Fig.  1d). The effect of treatment with a higher 
concentration of the p2 peptide (50–250 µM) on reverse 
transcription suggests that the p2 peptide may inter-
act with a host saturable target because the effect was 
saturated (data not shown). Therefore, we used the Y2H 
system because it is a very powerful tool for identifying 
unknown host-binding targets. Y2H analysis revealed the 
novel interaction between the p2 peptide and MT-CO1, 
and that Gln6 in the p2 peptide was important for the 
interaction with MT-CO1 (Fig.  2b). To the best of our 
knowledge, the direct binding of the p2 peptide to 
MT-CO1 has not been reported yet.
MT-CO1 is the main subunit of the MT-CO complex. 
Although the crystal structure of human MT-CO has not 
yet been reported, Tsukihara et  al. demonstrated that 


































































































































Fig. 5 p2-peptide increased intracellular ATP content in MDMs. a Cell morphology and expression of surface receptors on MDMs. Freshly prepared 
MDMs were stained with monoclonal antibodies specific for CD14 (MAb M5E2), CD4 (MAb OKT4), or CCR5 (MAb 45531.111) and analyzed by flow 
cytometry. b Comparison of intracellular ATP level between MT-4 and MDMs. c The infection with the CCR5-tropic HIVAD8 WT virus increased the 
intracellular ATP content in MDMs. In contrast, the intracellular ATP content after HIVNL-CH(AD8) p2(Q6A) infection was not significantly increased com-
pared with mock treatment. **p < 0.01, Nonrepeated measures ANOVA and Dunnett’s test. The mean values of at least three independent experi-
ments are shown. d p2(Q6A) mutant virus showed a significant decrease in the level of the late viral cDNA product in MDMs as compared with that 
in the WT virus. MDMs were infected with VSV-G-pseudotyped HIVNL-CHΔenv p2(Q6A). Reverse transcription products were determined by quantitative 
PCR analysis using late-stage primers (R/gag), as described in “Methods”. To normalize the amount of cellular DNA (100 ng) in the samples, a primer 
pair complementary to the first exon of the human β-actin gene was used
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three major subunits (MT-CO1, MT-CO2, and MT-CO3) 
form the catalytic core and are encoded by mitochondrial 
DNA. The remaining subunits are nucleus-encoded. The 
N214–F235 domain was completely conserved between 
human and bovine MT-CO1, and the crystal structure 
analysis of bovine heart MT-CO [13] demonstrated that 
the domain is exposed on the intermembrane space 
side of the inner membrane (Fig.  6, shown in yellow in 
the lower inset), suggesting that the p2 peptide is readily 
accessible to the domain of MT-CO1 (N214–F235). Actu-
ally, the p2 peptide directly activated the MT-CO positive 
control and native MT-CO in mitochondrial fractions 
in  vitro (Fig.  3b). Furthermore, the WT virus efficiently 
increased the intracellular ATP content in MT-4 cells and 
MDMs (Figs. 4b, 5c). These findings are the first demon-
stration of the functional interaction between the p2 pep-
tide and MT-CO1 and this interaction plays a key role in 
increasing intracellular ATP production in the target cell.
The nuclear import of the HIV-1 preintegration com-
plex (PIC) is an ATP-dependent process [14, 15], which 
suggests the involvement of the host cell nuclear trans-
port machinery and viral and host nuclear localization 
signals. HIV-1 PIC contains at least four karyophilic pro-
teins [viral (MA, IN, and Vpr) and host cell (LEDGF/p75) 
proteins]. Many studies demonstrated that the passage of 
HIV-1 PIC through the nuclear envelope is a necessary 
step in HIV infection of both dividing and nonproliferat-
ing cells [16–18]. Bukrinsky et al. demonstrated that the 
lack of two-LTR circle formation (as a marker of entry of 
viral DNA into the nucleus) under intracellular low-ATP-
content conditions is a consequence of the inhibition of 
nuclear import of HIV-1 DNA [14]. Furthermore, they 
reported that the synthesis of HIV-1 DNA in HIV-1-in-
fected cells was less efficient in ATP-depleted cell cul-
tures [14]. Consistent with these findings, the treatment 
with the Tat-p2 peptide showed significant increases in 
the levels of 2-LTR circle products, which are generally 
used as a marker of PIC nuclear import (Fig.  1b). Fur-
thermore, Figs. 4c and 5d show that the inhibition of an 
effective increase in intracellular ATP content in target 
cells decreased reverse transcription efficiency during the 
acute infection of the p2(Q6A) mutant virus. These find-
ings suggest that the p2 peptide more efficiently supply 
ATP for active nuclear import of HIV-1 PIC as a result of 
binding of the p2 peptide to MT-CO1 (Fig. 6).
Conclusions
We conclude that the p2 peptide is a viral positive allos-
teric modulator of MT-CO involved in the respiratory 
chain and more efficiently supplies ATP for active nuclear 
import of the HIV-1 preintegration complex. These are 
the initial findings showing that the enzymatic activity of 
MT-CO1 is positively regulated by the exogenous viral 
spacer p2 peptide. This study reveals a novel regulation 
step of early HIV-1 infection.
Methods
Cell culture
MAGIC-5 cells, which were engineered to express CCR5 
in HeLa-CD4-LTR/β-Gal cells by transfection with an 
expression vector for CCR5, were maintained at 37  °C 
in DMEM supplemented with 5 % fetal calf serum (FCS) 
containing 0.2  mg/ml G418 (Sigma-Aldrich Co., LLC), 
50 U/ml hygromycine (Sigma-Aldrich Co., LLC), 1  µg/
ml blasticidin A (Kaken Pharmaceutical Co., Ltd.), and 
1  µg/ml puromycin (Sigma-Aldrich Co., LLC) in 5  % 
CO2. T-cell line MT-4 cells, HEK293 cells, and 293T cells 
were maintained at 37 °C in RPMI-1640 and DMEM sup-
plemented with 10  % FCS containing 100  IU/ml peni-
cillin and 100  μg/ml streptomycin in 5  % CO2. TZM-bl 
cells were obtained from the NIH AIDS Research and 
Reference Reagent Program. TZM-bl cells are HeLa cell 
clones that were engineered to express CD4 and CCR5 
and contain integrated reporter genes for firefly lucif-
erase and E. coli β-galactosidase under the control of 
HIV-1 LTR, permitting the sensitive and accurate meas-
urements of infection. Human monocyte-derived mac-
rophages (MDMs) were prepared in accordance with the 
following protocol. PBMCs obtained using PANCOLL 
reagent (PAN Biotech, Aidenbach, Germany) were sus-
pended in RPMI 1640 medium supplemented with 1  % 
FCS at a density of 1 × 106 cells/ml, and seeded in dishes. 
Monocytes were enriched by allowing them to adhere to 
the dishes for 1 h at 37 °C, and non-adherent cells were 
removed by extensive wash with PBS. Next, the adher-
ent monocytes were differentiated into macrophages by 
culturing them with RPMI 1640 supplemented with 10 % 
FCS containing 100  ng/ml rhM-CSF. After 3  days, the 
cultures were replaced with fresh complete media after 
extensive wash with PBS to remove nonadherent cells, 
and incubated for another 2  days. At day 5, the purity 
of MDMs was routinely >95 % according to a flow cyto-
metric analysis of CD14 expression. Furthermore, the 
expression of CD4 and CCR5 was also confirmed by flow 
cytometry analysis.
Plasmids
The coding region of HIV-1 p2 was amplified by PCR 
using the primers P2-UP (5′-AGGATCCGCTGAAG 
CAATGAGCCAAGTA-3′) and P2-DN1 (5′-TTTA 
GATCTTTACATTATGGTAGCTGGATTTGT-3′), and 
cloned into the PstI and EcoRV sites of the pcDNA4/
HisMaxC plasmid (Life Technologies Corporation) 
(pcDNA4/HisMaxC-p2). Then, the coding sequence 
of the EGFP gene was cloned into the EcoRI and PstI 
sites of pcDNA4/HisMaxC-p2 (pcDNA4/EGFP-p2x1). 
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Furthermore, the tandem repeats of DNA fragments 
coding the p2 region (p2x9 and p2x17) were also ampli-
fied by a PCR-based method using the primers P2-UP 
(5′-AGGATCCGCTGAAGCAATGAGCCAAGTA-3′), 
P2-DN1 (5′-TTTAGATCTTTACATTATGGTAGCTG 
GATTTGT-3′), and P2-DN2 (5′-TTT AGA TCT TCC 
GAT TAT GGT AGC TGG ATT TGT-3′). The ampli-
fied DNA fragments were cloned into pcDNA4/His-
MaxC with the coding sequence of the EGFP gene. In 
pcDNA4/EGFP-p2x9 or pcDNA4/EGFP-p2x17, individ-




























Fig. 6 Schematic illustration showing the mechanism by which p2 peptide positively regulates HIV-1 infection. Although the actual molecular 
basis of the allosteric mechanism of the p2 peptide is still unclear, the findings of this study suggest that the p2 peptide is a viral positive allosteric 
modulator of MT-CO1 and more efficiently supplies ATP for the active nuclear import of HIV-1 PIC. The N214–F235 domain (shown in yellow in the 
lower inset) was completely conserved between human and bovine MT-CO1, and the crystal structure analysis of bovine heart MT-CO demonstrated 
that the domain is exposed on the intermembrane space side of the inner membrane. MT-CO-1 was shown in purple inside cytochrome c oxidase
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Viruses
The clade B laboratory-adapted strain HIV-1JRFL was 
used. The virus was propagated in a chronically HIV-
1JRFL-infected T cell line (Molt4-CCR5/JRFL) grown 
in a complete medium consisting of RPMI 1640 sup-
plemented with 10  % heat-inactivated defined FBS 
(HyClone), penicillin (100  IU/ml), and streptomycin 
(0.1  mg/ml). Single-round replication-defective VSV-G-
pseudotyped HIVNL-CHΔenv WT was produced by cotrans-
fection of 293T cells with pHCMV-G and pNL-CHΔenv 
[19, 20]. Furthermore, the infectious molecular clone 
pNL-CH [20], derived from the pNL4-3 clone of HIV-1, 
was used to prepare the CXCR4-tropic p2(Q6A) mutant 
virus. Point mutation was introduced into the p2 domain 
in pNL-CH by site-directed mutagenesis. The SpeI-ApaI 
fragment of the p2(Q6A) mutant was recloned into the 
full-length HIV expression plasmid pNL-CHSpeI-ApaI, 
which did not have the backbone SpeI-ApaI fragment. 
Finally, HIVNL-CH p2(Q6A) was produced by the transient 
transfection of HEK293 cells using pNL-CH p2(Q6A). 
Four days after transfection, the virus-containing super-
natant was collected and clarified by filtration through 
0.45-μm-pore-size filters. In addition, the CCR5-tropic 
p2(Q6A) mutant virus (HIVAD8 p2(Q6A)) was produced 
using pNL(AD8) [21] derivative that carries Q6A muta-
tion in the p2 domain. Finally, VSV-G-pseudotyped 
HIVNL-CHΔenv p2(Q6A) was produced by cotransfection of 
293T cells with pHCMV-G and pNL-CHΔenv p2(Q6A).
MAGIC‑5 assay
Viral infectivity was determined using MAGIC-5 cells 
[22]. The cells were seeded (1 ×  104  cells per well) and 
then infected with the HIVJRFL strain [2.16  ×  105  tis-
sue culture infective dose50 (TCID50)/ml, multiplicity of 
infection =  0.01] in the presence of the Tat-p2 peptide 
(GRKKRRQRRRARVLAEAMSQVTNTATIM) [11] or 
the Tat-scrambled peptide (GRKKRRQRRRARVLIAVS 
NMQTTAMATE) at the indicated concentrations and 
DEAE-dextran (20 μg/ml) for 48 h. The cells were fixed 
with 1  % formaldehyde-0.2  % glutaraldehyde in PBS for 
5  min, washed, and then stained with X-gal. Control 
experiments were carried out under identical condi-
tions in the presence of the Tat-scrambled peptide. The 
number of cells stained blue was expressed as a percent-
age (%) relative to the number of cells stained blue in the 
control.
Quantitative analysis of HIV‑1 reverse transcription 
during acute infection
De novo synthesized HIV-1 cDNA was analyzed using 
the protocol of Ikeda et  al. [23]. Briefly, the MAGIC-5 
cells (5 × 105 cells) were infected with the HIVJRFL strain 
(100  ng of HIV p24) in the presence of 10  µM Tat-p2 
peptide or 10  µM Tat-scrambled peptide and incubated 
for 24 h at 37 °C. Next, the cells were washed with PBS(−) 
twice and treated with DNase I (100 U; Takara) for 1 h. 
After DNase I treatment, the cells were washed with 
PBS(−) twice and incubated for 5 min at 37 °C in PBS(−) 
containing 0.25 % trypsin. After trypsinization, the cells 
were washed with PBS(−) twice and then digested in 
200  μl of digestion buffer [10  mM Tris–HCl (pH 8.0), 
150  mM NaCl, 10  mM EDTA, 0.1  % SDS, and 100  μg/
ml proteinase K] for 2 h at 50 °C. After heat-inactivating 
proteinase K for 10 min at 95 °C, the lysate was subjected 
to phenol–chloroform extraction and ethanol precipita-
tion. The resulting DNA pellet was resuspended in the 
distilled deionized water. To measure the amounts of 
late reverse transcription products, 2-LTR products and 
integrated (Alu) forms of viral cDNAs, the sample was 
examined by quantitative real-time PCR analysis using 
a primer pair specific for the R/gag, 2-LTR and Alu/gag 
region (M667, 5′-GGCTAACTAGGGAACCCACTG-3′; 
M661, 5′-CCTGCGTCGAGAGAGCT CCTCTGG-3′; 
2-LTR sense, 5′-GAG ATC CCT CAG ACC CTT TTA 
G-3′; 2-LTR antisense, 5′-GTC AGT CGA TAT CTG 
ATC CCT G-3′; Alu-specific primer, 5′-TCCCAGC 
TACTCGGGAGGCTGAGG-3′; AA55, 5′-CTG CTA 
GAG ATT TTC CAC ACT GAC-3′). To further deter-
mine whether the amounts of late reverse transcription 
products are increased by the intracellular expression of 
the p2 peptide, MAGIC-5 cells (2 × 105 cells) were trans-
fected with pcDNA4/EGFP-p2x1. At 24  h post-trans-
fection, EGFP-transduced and EGFP-p2x1-transduced 
MAGIC-5 cells were infected with the DNase I-treated 
single-round replication-defective virus (VSV-G-pseu-
dotyped HIVNL-CHΔenv WT, 10  ng of HIV p24). At 24  h 
postinfection, the amounts of late reverse transcription 
products were measured as described above.
To investigate the effect of p2(Q6A) mutation on 
reverse transcription, MT-4 cells (2 × 105 cells) or MDMs 
(2  ×  105  cells) were infected with the DNase I-treated 
virus (HIVNL-CH p2(Q6A), 100  ng of HIV p24; VSV-G-
pseudotyped HIVNL-CHΔenv p2(Q6A), 10 ng of HIV p24). At 
24 h post infection, the amounts of late reverse transcrip-
tion products were measured as described above and 
expressed as a percentage (%) relative to the amounts in 
the control experiment.
In vitro RT activity assay
To determine whether the p2 peptide could allosterically 
increase RT activity, the Tat-p2 peptide (GRKKRRQR 
RRARVLAEAMSQVTNTATIM), Tat-peptide (GRKKR 
RQRRRARVL), and p2 peptide (AEAMSQVTNTATIM) 
and a reverse transcription assay kit (F. Hoffmann-La 
Roche Ltd.) were used in this assay. Briefly, a solu-
tion containing 46  mM Tris–HCl, 266  mM potassium 
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chloride, 27.5  mM magnesium chloride, 9.2  mM DTT, 
digoxigenin (DIG)-labeled dUTP, biotin-labeled dUTP, 
dTTP, and poly(A) × oligo(dT)15 template/primer hybrid 
was added to the reaction tube containing the HIV-1 RT 
standard (8.62 fmol) preincubated for 0.5 h with the Tat-
p2 peptide, Tat-peptide, or p2 peptide at a ratio of 1:40, 
and then incubated for 1  h at 37  °C. After terminating 
the RT reaction, the reaction mixture was transferred to 
streptavidin-coated microtitre plates. DIG-labeled DNA 
was detected with an anti-DIG-POD conjugate, reacted 
with 2, 2-azino-di(3-ethylbenzthiazoline) sulfonic acid, 
and quantified by measuring OD at 405/490  nm. HIV-
1-RT activity assay was performed as described in the kit 
protocol.
Yeast two‑hybrid plasmid construction and yeast 
two‑hybrid library screening
The yeast expression plasmid pGBKT7 (bait) contain-
ing TRP1 selection markers was used (Clontech). The 
HIV-1 p2 coding sequence from pNL4-3 was subcloned 
in-frame with the DNA-binding domain of the transcrip-
tion factor Gal4 (Gal4 DNA-BD) into the EcoRI/BamH1 
sites of pGBKT7 to generate the pGBKT7-p2 plasmid. 
Before screening, the bait protein (GAL4 DBD/p2 fusion 
protein) was tested for its autoactivity in the absence of 
a prey HeLa S3 library. Human cDNA library screening 
was performed by mating the Y2Hgold expressing the 
bait protein with the Y187 strain pretransformed with the 
HeLa S3 (normalized) library encoded by the pGADT7 
AD vector (Clontech) in accordance with the manufac-
turer’s protocol using double-drop-out (DDO) (without 
tryptophan and leucine with or without aureobasidin A 
and X-α-Gal) and quadruple-drop-out (QDO) (without 
tryptophan, leucine, adenine, and histidine and with or 
without aureobasidin A and X-α-Gal) selective medium 
agar plates. For cotransformation assay using the positive 
clones from the initial Y2H screening, the bait plasmid 
(pGBKT7-p2) and prey plasmid derived from the HeLa 
S3 cDNA library (pGADT7-MT-CO1) were cotrans-
formed into Y2Hgold to validate the interactions in yeast. 
Furthermore, the alanine scanning mutagenesis in the 
highly conserved AEAMSQ motif of the p2 peptide in 
pGBKT7-p2 was used to determine the contribution of 
a specific residue to the interaction between the p2 pep-
tide and MT-COI. The pGBKT7-p2, pGBKT7-p2(E2A), 
pGBKT7-p2(M4A), pGBKT7-p2(S5A), pGBKT7-
p2(Q6A), and pGBKT7 vectors were cotransformed with 
pGADT7-MT-CO1 and plated on DDO/X and QDO/
X/A. On the other hand, the bait plasmid (pGBKT7-53 
or pGBKT7-Lam) was cotransformed into Y2HGold with 
the prey plasmid (pGADT7-T) to serve as a positive or 
negative control, respectively (data not shown). The AD/
library cDNA inserts were sequenced and analyzed using 
the NCBI BLASTP program.
Western immunoblot analysis
To determine the effect of the p2 peptide on MT-CO1, 
MAGIC-5 cells (3  ×  105  cells) were transfected with 
pcDNA4/EGFP-p2x1. At 48  h posttransfection, EGFP-
transduced MAGIC-5 cells were lysed with 62.5  mM 
Tris–HCl, 2  % SDS, 10  % glycerol (pH 6.8), and 10  % 
2-mercaptoethanol. The lysate was subjected to SDS-
PAGE, and separated products were transferred to a 
polyvinylidene difluoride membrane. The membrane 
was stained with an anti-Xpress monoclonal antibody 
(Life Technologies, Inc.), an anti-MT-CO1 polyclonal 
antibody (Abcam), or an anti-actin monoclonal antibody 
(Oncogene™ Research Products). To monitor the pro-
cessing of Pr55gag into a mature capsid protein, the viral 
lysates from HIVNL-CH p2(Q6A) were examined by western 
immunoblot analysis using an HIV-1-positive plasma.
In vitro mitochondrial cytochrome c oxidase activity assay
To investigate the effect of the p2 peptide on the MT-CO 
positive control (Kit Item, KC310100-6) or native 
MT-CO in mitochondrial fractions from MAGIC-5 cells, 
we used an in vitro cytochrome c oxidase activity assay 
kit (BioChain Institute, Inc.) to measure the decrease 
in absorbance at 550  nm of ferrocytochrome c caused 
by its oxidation to ferricytochrome c by MT-CO in the 
presence or absence of the p2 peptide (final concentra-
tions =  0, 80, and 160  µM, AEAMSQVTNTATIM). To 
prepare the native MT-CO, mitochondria were isolated 
from MAGIC-5 cells (1 × 108 cells) using a mitochondria 
isolation kit for cultured cells (BioChain Institute, Inc.) 
and treated with n-dodecyl β-D-maltoside, which is one 
of the few detergents that maintain the cytochrome c oxi-
dase dimer in solution at a low detergent concentration, 
thereby maintaining enzyme activity. Enzyme activity was 
determined colorimetrically by monitoring the oxidation 
of reduced cytochrome c as an absorbance decrease at 
550  nm using a UV–VIS recording spectrophotometer 
(SHIMAZU). To further investigate the direct effect of 
the p2 peptide on mitochondria-derived MT-CO, sodium 
azide was used because it is commonly used in  vitro as 
a rapid and reversible inhibitor of MT-CO [24, 25]. The 
effect of the p2 peptide (160  µM) on mitochondria-
derived MT-CO pretreated with 10 mM sodium azide for 
15 min was also examined in the same way.
Confocal microscopy
HeLa cells (5 ×  104) were seeded in 400 μl of medium/
well on 8-well chambered Lab-Tek II chamber slides 
(Thermo Fisher Scientific Inc.). After 24 h, the cells were 
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transfected with pEGFP-p2x1, pEGFP-p2x9, or pEGFP-
p2x17 using Lipofectamine LTX (Life Technologies, Inc.). 
After 24  h posttransfection, the transiently transfected 
MAGIC-5 cells were incubated for 0.5  h in a medium 
containing 200 nM MitoTracker (Life Technologies, Inc.) 
and washed with PBS(−). The cells were fixed by incu-
bation with 200 μl of 1 % paraformaldehyde for 15 min, 
washed with PBS(−), and incubated in a cold 100  % 
methanol for 10  min. After that, the cells were stained 
with 4′, 6-diamidino-2-phenylindole (DAPI) for 5  min. 
The slides were mounted in VECTASHIELD (Vector 
Labs). Images were taken using a ConfoCor3 ZEN2009 
confocal microscope (Carl Zeiss, Inc.).
Proteinase K digestion of isolated mitochondria
MAGIC-5 cells were transfected with pEGFP-p2x1 using 
Lipofectamine LTX (Life Technologies, Inc.). After 24 h 
posttransfection, the mitochondria were freshly isolated 
using a mitochondria isolation kit (BioChain Institute, 
Inc.). The mitochondria were incubated in 20 µl of stor-
age buffer included in the kit (BioChain Institute, Inc.) 
alone or in the presence of proteinase K (0.05  μg/ml). 
After 30 min of incubation, 20 μl of SDS-loading buffer 
was added and the mixture was then boiled for 5 min and 
examined immediately by Western immunoblot analysis 
using an anti-Xpress antibody (Life Technologies, Inc.), 
anti-Bcl-2 antibody (Santa Cruz Biotechnology, Inc.), or 
rabbit anti-MT-COI polyclonal antibody (Abcam Plc.).
Determination of cytosolic ATP
The ATP Bioluminescence Assay kit CLS II (Roche Diag-
nostics Corporation) was used in accordance with the 
manufacturer’s recommendations to analyze the effect of 
HIV infection on intracellular ATP content. MT-4 cells 
(1  ×  105  cells) were infected with HIVNL-CH or HIVNL-
CH p2(Q6A) (100 ng of p24 antigen) and cultured for 12 h 
at 37  °C. The cells were washed with PBS(−) twice and 
then digested with the cell lysis reagent included in the 
kit. ATP content was measured using the ATP Biolumi-
nescence Assay kit CLS II in accordance with the manu-
facturer’s instructions. To further examine the effect of 
the p2 peptide on intracellular ATP level in MDMs, the 
cells (4 × 105 cells) were infected with HIVAD8 or HIVAD8 
p2(Q6A) (500  ng of p24 antigen). Intracellular ATP level 
was measured in the same way.
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